Skip to content

English

繁體中文

syneuRx-logo
  • About
    • Mission
    • Leadership Team
    • Major Milestone
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNB01
    • SND13
    • SND12
    • SND11
  • Newsroom
    • Press Release
    • Publication
    • Media
  • Contact
Menu
  • About
    • Mission
    • Leadership Team
    • Major Milestone
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNB01
    • SND13
    • SND12
    • SND11
  • Newsroom
    • Press Release
    • Publication
    • Media
  • Contact

Blog

Q&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

  • Post author:admin
  • Post published:March 30, 2022
  • Post category:Blog

Q&A with SyneuRx Chief Scientist and CEO, Dr. Emil Tsai: What Are The Top Symptoms of The BA.2 Variant and Is It a Major Cause of Concern? Since the beginning…

Continue ReadingQ&A with SyneuRx Chief Scientist and CEO., Emil Tsai, M.D.–Ph.D., M.A.S.: What are the top Symptoms of the BA.2 Variant and is it a Major Cause for Concern?

Privacy Policy

Terms of Use

Contact

About

  • Mission
  • Leadership Team
  • Major Milestone

Research

  • Antiviral Platform
  • NMDA Platform
  • Pipeline

Trials

  • SNB01
  • SND13
  • SND12
  • SND11

Newsroom

  • Press Release
  • Publication
  • Media
SyneuRx International (Taiwan) Corp.
Copyrights © 2013 SyneuRx Corp. All rights reserved.

Privacy Policy

Terms of Use

Contact

About

  • Mission
  • Leadership Team
  • Major Milestone

Research

  • Antiviral Platform
  • NMDA Platform
  • Pipeline

Trials

  • SNB01
  • SND13
  • SND12
  • SND11

Newsroom

  • Press Release
  • Publication
  • Media
SyneuRx International (Taiwan) Corp.
Copyrights © 2013 SyneuRx Corp. All rights reserved.